目的 研究針對(duì)慢性盆腔炎應(yīng)用散結(jié)鎮(zhèn)痛膠囊和頭孢地尼聯(lián)合治療的臨床效果。方法 納入新疆醫(yī)科大學(xué)第一附屬醫(yī)院2022年1月—2024年11月收治的88例慢性盆腔炎患者，進(jìn)行分組（隨機(jī)數(shù)字表法）研究，每組各44例。對(duì)照組口服頭孢地尼膠囊，0.1 g/次，3次/d。以此為基礎(chǔ)，治療組加用散結(jié)鎮(zhèn)痛膠囊治療，餐后30 min口服，4粒/次，3次/d。兩組療程14 d。評(píng)估兩組臨床療效，比較治療前后兩組相關(guān)評(píng)分[簡(jiǎn)式抑郁–焦慮–壓力量表（DASS-21）、慢性盆腔炎功能量表（FS-CPID）評(píng)分]，盆腔包塊最大徑，血液流變學(xué)指標(biāo)血漿黏度（PV）、紅細(xì)胞聚集指數(shù)（EAI）及血清白細(xì)胞介素-1β（IL-1β）、IL-6水平。結(jié)果 治療組總有效率是95.45%，較對(duì)照組的81.82%更高（P＜0.05）。同治療前相比，兩組病情各項(xiàng)評(píng)分（主癥、次癥、盆腔局部體征等）和總分在治療后都降低（P＜0.05），DASS-21評(píng)分、盆腔包塊最大徑亦降低（P＜0.05）；治療組較對(duì)照組更低（P＜0.05）。同治療前相比，兩組患者FS-CPID評(píng)分在治療后都增加（P＜0.05），治療組較對(duì)照組更高（P＜0.05）。治療后，兩組PV、EAI和血清IL-1β、IL-6水平都低于組內(nèi)治療前（P＜0.05），且治療后治療組血液流變學(xué)指標(biāo)和血清因子水平明顯低于對(duì)照組（P＜0.05）。結(jié)論 散結(jié)鎮(zhèn)痛膠囊聯(lián)合頭孢地尼治療慢性盆腔炎能有效促進(jìn)患者癥狀、體征減輕及盆腔包塊消除，抑制盆腔血液循環(huán)障礙和炎癥反應(yīng)，利于整體改善患者病情和生活質(zhì)量，緩解不良情緒。

Objective To investigate the efficacy of Sanjie Zhentong Capsules combined with cefdinir in the treatment of chronic pelvic inflammatory disease (CPID). Methods Eighty-eight CPID patients admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2022 to November 2024 were enrolled and divided into two groups (via random number table), with 44 cases each. The control group received Cefdinir Capsules (oral, 0.1 g/dose, 3 times daily). Based on this, the treatment group additionally received Sanjie Zhentong Capsules (oral, 4 pills/dose, 3 times daily, 30 min after meals). Both groups were treated for 14 days. Clinical efficacy was evaluated, and pre-treatment and post-treatment scores were compared, including the Depression-Anxiety-Stress Scale-21 (DASS-21), Chronic Pelvic Inflammatory Disease Function Scale (FS-CPID), maximum diameter of pelvic masses, hemorheological indices (plasma viscosity, PV; erythrocyte aggregation index, EAI), and serum levels of interleukin-1β (IL-1β) and IL-6. Results The total effective rate of treatment group was 95.45%, which was higher than that of control group at 81.82% (P < 0.05). Compared with before treatment, the scores of each item of the disease (main symptoms, secondary symptoms, local pelvic signs, etc.) and the total score of both groups decreased after treatment (P < 0.05), and the DASS-21 score and the maximum diameter of pelvic masses also decreased (P < 0.05). The treatment group was lower than the control group (P < 0.05). Compared with before treatment, the FS-CPID scores of both groups of patients increased after treatment (P < 0.05), and the score of the treatment group was higher than that of the control group (P < 0.05). After treatment, the levels of PV, EAI, and serum IL-1β and IL-6 in both groups were lower than those before treatment within the groups (P < 0.05), and the hemorheological indicators and serum factor levels in the treatment group were significantly lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Sanjie Zhentong Capsules and cefdinir effectively alleviates symptoms/signs, promotes pelvic mass resolution, mitigates pelvic circulation disorders and inflammatory responses, and improves overall disease status, quality of life, and psychological well-being in CPID patients.

R984